Targets › CD40
19 programs from 18 companies in 29 trials: 22 Phase 1, 7 Phase 2; Oncology, Immunology, Metabolic and endocrine; next expected readout Dec 2026.
Receptor for TNFSF5/CD40LG. Transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells, leading to induction of immunoglobulin secretion (By similarity). (UniProt, P25942)
Open in Phaseline: the race on CD40, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Roswell Park Cancer Institute | CDX-1140 Tumor necrosis factor receptor superfamily member 5 agonist | CD40 | Phase 2 | Ovarian Clear Cell Adenocarcinoma | Mar 2027 |
| Memorial Sloan Kettering Cancer Center | 2141-V11 Antibody CD40 agonist monoclonal antibody | CD40 | Phase 2 | Prostate Cancer; Non-muscle Invasive Bladder Cancer; Esophageal Cancer | Nov 2027 |
| National Cancer Institute (NCI) | CDX-1140 Tumor necrosis factor receptor superfamily member 5 agonist | CD40 | Phase 2 | Head and Neck Squamous Cell Carcinoma; Biliary Cancer | Nov 2027 |
| Veloxis Pharmaceuticals | VEL-101 CD40-CD154 pathway antagonist (costimulation blockade) | CD40 | Phase 2 | Transplantation, Kidney | Oct 2028 |
| Novartis | Iscalimab (CFZ533) Tumor necrosis factor receptor superfamily member 5 inhibitor | CD40 | Phase 2 | Hidradenitis Suppurativa | – |
| RANI Therapeutics | PG-102 Tumor necrosis factor receptor superfamily member 5 inhibitor | CD40 | Phase 1 | Obesity; Type 2 Diabetes Mellitus (T2DM) | Dec 2026 |
| Providence Health & Services | CDX-1140 Tumor necrosis factor receptor superfamily member 5 agonist | CD40 | Phase 1 | Malignant Epithelial Neoplasms | Dec 2026 |
| University of Southern California | CDX-1140 Tumor necrosis factor receptor superfamily member 5 agonist | CD40 | Phase 1 | Anatomic Stage IV Breast Cancer AJCC v8 | Jan 2027 |
| Genmab | GEN1042 Bispecific antibody targeting CD40 and 4-1BB (TNFRSF18); DuoBody format | CD40, TNFRSF18 | Phase 1 | Malignant Solid Tumor | Jan 2027 |
| Akamis Bio | NG-350A Tumour-selective anti-CD40-expressing adenoviral vector | CD40 | Phase 1 | Locally Advanced Rectal Cancer (LARC) | Jan 2027 |
| AbbVie | Giloralimab (ABBV-927) Tumor necrosis factor receptor superfamily member 5 agonist | CD40 | Phase 1 | Advanced Solid Tumors Cancer; Cancer | Mar 2027 |
| M.D. Anderson Cancer Center | Sotigalimab Tumor necrosis factor receptor superfamily member 5 agonist | CD40 | Phase 1 | Metastatic Colorectal Adenocarcinoma | May 2027 |
| Darell Bigner | 2141-V11 Anti-CD40 monoclonal antibody | CD40 | Phase 1 | Glioma, Malignant; Newly Diagnosed MGMT Unmethylated Glioblastoma; Recurrent Glioblastoma IDH Wildtype | Jun 2027 |
| AbbVie | Azirkitug CD40 agonist monoclonal antibody | CD40 | Phase 1 | Non-Small Cell Lung Cancer | Jul 2027 |
| University of Texas Southwestern Medical Center | CDX-1140 Tumor necrosis factor receptor superfamily member 5 agonist | CD40 | Phase 1 | HER2-negative Breast Cancer | Apr 2028 |
| Xencor | Plamotamab CD40-engaging bispecific antibody | CD40 | Phase 1 | Rheumatoid Arthritis | Jun 2028 |
| University of California, San Diego | mitazalimab (CD40 antibody) CD40 agonist antibody | CD40 | Phase 1 | Pancreatic Cancer | Aug 2028 |
| Roche | Selicrelumab Tumor necrosis factor receptor superfamily member 5 agonist | CD40 | Phase 1 | Metastatic Breast Cancer | Sep 2030 |
| Alligator Bioscience | mitazalimab CD40 agonist | CD40 | Phase 1 | Metastatic Pancreatic Ductal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma | – |
Malignant Epithelial Neoplasms (2) Malignant Solid Tumor (2) Glioma, Malignant (1) Newly Diagnosed MGMT Unmethylated Glioblastoma (1) Recurrent Glioblastoma IDH Wildtype (1) Head and Neck Squamous Cell Carcinoma (1) Biliary Cancer (1) Non-Small Cell Lung Cancer (1) HER2-negative Breast Cancer (1) Anatomic Stage IV Breast Cancer AJCC v8 (1) Pancreatic Cancer (1) Advanced Solid Tumors Cancer (1)
mixed (9), antibody (5), small molecule (4), protein or peptide (1)
AbbVie (2) Darell Bigner (1) National Cancer Institute (NCI) (1) University of Texas Southwestern Medical Center (1) University of Southern California (1) University of California, San Diego (1) Providence Health & Services (1) Xencor (1) Genmab (1) RANI Therapeutics (1) Roche (1) Akamis Bio (1) Alligator Bioscience (1) M.D. Anderson Cancer Center (1) Memorial Sloan Kettering Cancer Center (1) Veloxis Pharmaceuticals (1) Roswell Park Cancer Institute (1) Novartis (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.